Barrington Research Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE - Get Free Report) had its price target lowered by equities research analysts at Barrington Research from $108.00 to $95.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the medical instruments supplier's stock. Barrington Research's target price points to a potential upside of 54.37% from the company's previous close.

Other research analysts have also recently issued research reports about the stock. Needham & Company LLC restated a "buy" rating and issued a $112.00 target price on shares of Haemonetics in a report on Tuesday, December 3rd. JPMorgan Chase & Co. started coverage on Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price objective on the stock. Finally, Raymond James upgraded Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 target price on the stock in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $101.67.

Haemonetics Stock Up 1.5 %

Shares of HAE stock traded up $0.90 on Friday, reaching $61.54. 915,630 shares of the stock were exchanged, compared to its average volume of 992,957. Haemonetics has a twelve month low of $58.80 and a twelve month high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.09 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 0.98 and a beta of 0.39. The business's 50 day moving average price is $75.84 and its 200 day moving average price is $78.01.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, sell-side analysts expect that Haemonetics will post 4.59 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier's stock valued at $337,722,000 after purchasing an additional 363,702 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of Haemonetics by 14.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock valued at $98,716,000 after buying an additional 164,111 shares in the last quarter. Royce & Associates LP grew its holdings in Haemonetics by 2.6% during the third quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier's stock worth $97,304,000 after acquiring an additional 30,868 shares during the period. Geode Capital Management LLC lifted its holdings in Haemonetics by 1.8% in the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier's stock valued at $95,986,000 after acquiring an additional 21,547 shares during the period. Finally, Boston Trust Walden Corp boosted its position in shares of Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.